Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer

Human Molecular Genetics

Volumn 4, Issue 2, 1995, Pages 231-236

  Risch, A ^a   Wallace, D M A ^b   Bathers, S ^b   Sim, E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

ACETYLATION; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BLADDER NEOPLASMS; CARCINOGENS; CAUCASOID RACE; COMPARATIVE STUDY; ENGLAND; FEMALE; GENOTYPE; HUMAN; MALE; MIDDLE AGE; OCCUPATIONAL EXPOSURE; PHENOTYPE; RISK FACTORS; SMOKING; SUPPORT, NON-U.S. GOV'T;

EID: 0028909978     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/4.2.231     Document Type: Article

References (42)

1. The Office of Population Censuses and Surveys (OPCS) (1994) Cancer Statistics registration—Registrations of cancer diagnosed in 1988, England and Wales. Series MB1 no.20. London:HMSO.
2. Rehn, L. (1895) Blasengeschwuelste bei Fuchsin-Arbeitern. Arch. Klin. Chir., 50, 588-600.
3. Case, R.A., Hosker, M.E., McDonald, D.B. and Pearson J.T. (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Bril. J. Ind. Med., 11, 75-104.
4. Wallace, D.M.A. (1988). Occupational urothelial cancer. Br. J. Urol., 61, 175-182.
5. The British Association of Urological Surgeons (BAUS) Subcommittee on Industrial Bladder Cancer (1988) Occupational bladder cancer a guide for clinicians. Br. J. Urol., 61, 183-191.
6. Hoffman, D. and Wynder, E.L. (1986) Chemical constituents and bioactivity of tobacco smoke. In Zaridze, D.G., Peto, R. (eds) Tobacco: A Major International Health Hazard. LARC scientific publications no. 74, Lyon, pp. 145-165.
7. Doll, R. (1971) Cancers related to smoking. In Richarson, R.G. (ed.), Proceedings of the Second World Conference on Smoking and Health. 1971 Sept. 20-24; London. London, Pitman Medical, pp. 10-23.
8. Hein, D.W., Ferguson, R.J., Doll, M.A., Rustan, T.D. and Gray, K. (1994) Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol Genet., 3, 247-249.
9. Miller, E.C. and Millcr, J.A. (1981) Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer, 47, 2327-2345.
10. Grant, D.M., Josephy, P.D., Lord, H.L. and Morrison, L.D. (1992) Salmonella Tyhphimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res., 52, 3961-3964.
11. Bartsch, H., Caporaso, N., (1994) Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature, 369, 154-156.
12. Price-Evans, D.A., Manley, K. A. and McKusick, U.A. (1960) Genetic control of isoniazid metabolism in man. Brit. Med. J 2, 485-491.
13. Palamanda, J., Hickman, D., and Unadkat, J.D. (1994) Dapsone acetylation by human liver N-acetyltransferase (NAT) and interaction with anti-opportunistic infection drugs. Drug Metabolism. In Press.
14. Hickman, D. and Sim, E. (1991) N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem. Pharmacol., 42, 1007-1014.
15. Deguchi, T., Mashimo, M. and Suzuki, T. (1990) Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N- acetyltransferase in human liver. J. BioL Chem., 265, 12757-12760.
16. Grant, D.M. (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics, 3, 45-50.
17. Blum, M., Grant D.M, McBnde, W., Heim, M. and Meyer, U.A. (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell BioL, 9, 193-203.
18. Vatsis, K.P, Martel, K.J. and Weber, W. (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sei. USA, 88, 6333-6337.
19. Blum, M., Demierre A., Grant, D., Heim, M. and Meyer, U.A. (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl Acad. Set. USA, 88, 5237-5241.
20. Hickman, D., Risch, A., Camilleri, J.P. and Sim, E. (1992) Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics, 2, 217-226.
21. Vatsis, K.P., Weber, W.W., Bell, D.A., Dupret, J-M., Evans, D.A.P., Granfi, D.M., Hein, D.W., Hickman, D., Lin, H.J., Meyer, U., Relling, M.V., Sim, E., Suzuki, T. and Yamazoe, Y. (1995) Nomenclature for N- acetyltransferases. Pharmacogenetics. In Press.
22. Vatsis, K.P. and Weber, W.W. (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch. Biochem. Biophys., 301, 71-76.
23. Kadlubar, F.F. (1991) Carcinogenic aromatic amine metabolism and DNA adduct detection in humans. In Ernster, L., Esumi, H., Fujii, Y., Gelboin, H.V., Kato, R., Sugimura, T. (eds) Xenobiotics and Cancer. Japan Sei Soc Press, Tokyo/Taylor & Francis Ltd. London, pp. 329-338.
24. Cartwright, A., Glashan, R.W., Rogers, H.J., Ahmad, R.A., Barham-Hall, D., Higgins, E. and Kahn, M. A. (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2, 842-846.
25. Caporaso, N., Landi, M.T., Vineis, P. (1991) Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4-19.
26. Bell, D.A., Taylor, J.A., Butler, M.A., Stephens, E.A., Wiesq, J., Brubaker, L.H., Kadlubar, F.F. and Luder, G.W. (1993) Genotype/ phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylalor allele common in African-Americans. Carcinogenesis, 14, 1689-1692.
27. Hayesjlb, B.I., W. Rothman, Broly, F., Caporaso, N., Feng, P., You, X., Yin, S., Woosley, R.L. and Meyer, U.A. (1993) N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis, 14, 675-678.
28. Yu, M.C., Taghizadeh, K., Tannenbaum, K., Chan, K.K., Henderson, B.E. and Ross, R.K. (1994) Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black and Asian men in Los Angeles, California. J. Natl Cancer Inst., 86, 712-716.
29. Mommsen, S., Barfod, N.M. and Aagaard, J. (1985) N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low risk population. Carcinogenesis, 6, 199-201.
30. Sim, E. and Hickman, D. (1991) Polymorphism in human N- acetyltransferase—the case of the missing allele. Trends Pharmacol Sei., 12, 211-213.
31. Lin HJ., Han, C.Y., Lin, B.K. and Hardy, S. (1994) Ethnic distrbution of slow acetylator mutations in the N-acetyltransferase (NAT2) gene. Pharmacogenetics, 4, 125-134.
32. Davies, J.L., Kawaguchi, Y, Bennetq, S.T., Copeman, J.B., Cordell, HJ., Pritchard, L.E., Reed W., Gough, S.C.L., Jenkins, S.C., Palmer, S.M., Balfour, K.M., Rowe, B.R., Farrall, M., Bamett, A.H., Bain, S.C. and Todd, J.A. (1994) A genome-wide search for human type 1 diabetes susceptibility genes. Nature, 371, 130-136.
33. Kato, R. and Yamazoe, Y. (1994) Metabolic Activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metabolism Rev., 26, 413-430.
34. Smith J., Bebruin, L., Josephy, P.D. and Eling, T.E. (1992) Mutagenic activation of benzidine requires prior bacterial acetylation and subsequent conversion by prostaglandin-H synthase to 4-nitro- 4(acetylamino)biphenyl. Chem. Res. Toxicol, 5, 431-439.
35. Butler, M.A., Iwasaki, M., Guengerich, F.P. and Kadlubar, F.F. (1989) Human cytochrome P-450p, (P450IA2), the phenacetin O-deethylase, is primarily resposible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad Sei. USA, 86, 7696-7700.
36. Fleming, C.M., Persad, R., Kaisary, A., Smith, P., Adedoyin A., Porter, J., Wilkinson, G.R. and Branch, R.A. (1994) Low activity of dapsone N- hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics, 4, 199-207.
37. Sarkis, A., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J., Fair, W.R., Herr, H.W. and Reuter, V.E. (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J. Natl Cancer Inst., 85, 53-59.
38. Benedict, W.F. (1992) Altered RB expression is a prognostic clinical marker involved in human bladder tumorigenesis. J. Cell. Biochem., 161 (Suppl), 69-71.
39. Silverman, D.T., Hoover, R.N., Mason, TJ. and Swanson, G.M. (1986) Motor exhaust-related occupations and bladder cancer. Cancer Res., 46, 2113-2116.
40. Doll, R., Peto, R., Wheatley, K., Gray, R. and Sutherland, J. (1994) Mortality in relation to smoking: 40 years’ observations on male British doctors. Brit. Med. J., 309, 901-911.
41. Hickman, D., Risch, A., Buckle, V., Spurr, N.K., Jeremiah, S.J., McCarthy A. and Sim, E. (1994) Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J., 297, 441-445.
42. Knowles, M.A., Shaw, M.E. and Proclor, A.J. (1993) Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene, 8, 1357-1364.